Matching articles for "Lomaira"
Issue 1734 · August 4, 2025
Drugs and Devices for Weight Management

Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI,…

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):121-8 doi:10.58347/tml.2025.1734a
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding pharmacologic treatment for weight loss. Guidelines on pharmacologic treatment of obesity from the American Gastroenterological Association (AGA) were last updated in 2022.
Issue 1734 · August 4, 2025
Comparison Table: Some Drugs for Weight Management (online only)

View the Comparison Table: Some Drugs for Weight Management

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e127-30 doi:10.58347/tml.2025.1734b
View the Comparison Table: Some Drugs for Weight Management
Issue 1651 · May 30, 2022
Drugs and Devices for Weight Management

Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a…

Med Lett Drugs Ther. 2022 May 30; 64(1651):81-8
Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight loss.
Issue 1651 · May 30, 2022
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)

View the Comparison Table: Some FDA-Approved Drugs for Weight Management

Med Lett Drugs Ther. 2022 May 30; 64(1651):e89-91
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Issue 1548 · June 4, 2018
Diet, Drugs, Devices, and Surgery for Weight Management

Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10%…

Med Lett Drugs Ther. 2018 Jun 4; 60(1548):91-8
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs are FDA-approved for weight reduction and maintenance (see Table 1), and procedures such as endoscopic placement of dilated balloons have produced beneficial short-term results (see Table 2), but bariatric surgery has been the most effective intervention for sustainable long-term weight loss and reduction of obesity-related comorbidities.
Issue 1548 · June 4, 2018
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)

View the Comparison Table: Some FDA-Approved Drugs for Weight Management

Med Lett Drugs Ther. 2018 Jun 4; 60(1548):e98-100
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Issue 1509 · December 5, 2016 Free
In Brief: Phentermine (Lomaira) for Weight Loss

The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):158
The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only approved for short-term use (a few weeks) in adults with a body mass index (BMI) ≥30 kg/m 2 , or with a BMI ≥27 kg/m 2 in addition to a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes. Phentermine has been available alone and in combination with topiramate for years. 1 Lomaira was approved by the FDA under an abbreviated new drug application (ANDA) and is considered a generic drug. Its approval was based on the results of earlier phentermine trials. No studies are available comparing the efficacy and safety of Lomaira to standard doses of phentermine or to any other drug approved for weight loss. Like other sympathomimetic amines approved for weight loss, Lomaira is classified as a schedule IV controlled substance. All sympathomimetics can increase heart rate, raise blood pressure, and cause nervousness and insomnia. 2 Phentermine is contraindicated for use in patients with cardiovascular disease, hyperthyroidism, glaucoma, or a history of drug abuse, and in pregnant women. It should not be used while taking, and for 14 days after stopping, a monoamine oxidase (MAO) inhibitor because of the risk of hypertensive crisis. Diet, drugs, and surgery for weight loss. Med Lett Drugs Ther 2015; 57:21. SZ Yanovski and JA Yanovski. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311:74. Download complete U.S. English article